Trial · NCT05288842
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
NCT05288842, Recruiting, University Hospital, Lille
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tanycytes in Alzheimer's Disease and Frontotemporal Dementia. Trials, record NCT05288842. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05288842
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
- NCT number
- NCT05288842
- Status
- Recruiting
- Enrollment
- 102 participants, estimated
- Lead sponsor
- University Hospital, Lille
- Conditions
- Alzheimer Disease, Frontotemporal Dementia
- Interventions
- Lumbar puncture, blood sample
- First posted
- 2022-03-21
- Last updated
- 2026-05-18
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean CSF-to-blood ratio (CBR) of leptin concentration. | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Leptin concentration in blood and CSF (in the pg/mL range) will be measured by enzyme-linked immunosorbent assay (ELISA). |
| Secondary | Mean of the CSF-to-blood ratio (CBR) of hypothalamus-related hormones | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | CSF-to-blood ratio (CBR) of hypothalamus-related hormones |
| Secondary | Blood metabolomics | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Blood and CSF metabolites will be measured by LC MS/MS.Will be used a mix of targeted and untargeted approach for metabolomics using the Thermo Q-Exactive Orbitrap. |
| Secondary | CSF metabolomics | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Blood and CSF metabolites will be measured by LC MS/MS.Will be used a mix of targeted and untargeted approach for metabolomics using the Thermo Q-Exactive Orbitrap. |
| Secondary | Correlation coefficient between leptin CBR and general cognitive functioning assessed by the Mattis Dementia Rating Scale (MDRS)6 | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Correlation coefficient between leptin CBR and general cognitive functioning |
| Secondary | Correlation coefficients between leptin CBR and performances in a neuropsychological battery assessing the function of affective and social cognition in each AD and FTD groups | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Correlation coefficients between leptin CBR and performances |
| Secondary | Correlation coefficients between leptin CBR and behavioral, and psychological symptoms of dementia | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Correlation coefficients between leptin CBR and behavioral, and psychological symptoms |
| Secondary | Correlation coefficients between leptin CBR and putative symptoms/markers of hypothalamus dysfunction | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Correlation coefficients between leptin CBR and putative symptoms/markers |
| Secondary | Correlation coefficients between leptin CBR and changes in resting metabolic activity assessed by indirect calorimetry through | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Correlation coefficients between leptin CBR and changes in resting metabolic activity |
| Secondary | Correlation coefficients between leptin CBR and the following CSF biomarkers | At visit 2, occurring 1 to 90 days after visit 1(Baseline) | Correlation coefficients between leptin CBR and the following CSF biomarkers |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05288842
GET https://conductscience.org/api/trials/v1/NCT05288842/registered